VANCOUVER, BC, September 20, 2007 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received CE Mark approval to begin marketing additional diameters of its Quill™ Self-Retaining System (SRS) Polydioxanone (PDO) product line in Europe. The Quill™ SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. With CE Mark approval to market the additional 3-0 and 4-0 sizes of Quill™ SRS PDO, Angiotech now offers diameters ranging from sizes 2 to 4-0 in Europe. “The availability of these additional PDO sizes in Europe will allow our sales force to offer an even broader range of Quill™ SRS products, ensuring we have multiple solutions for a variety of wound closure and tissue approximation procedures,” said Dr. Santi Corsaro, Vice President, Sales & Marketing (OUS) for Angiotech. Angiotech plans to exhibit the Quill™ SRS product line at the upcoming Annual Meeting of the American Society of Plastic Surgeons (ASPS) to be held on October 26-31, 2007 in Baltimore, MD. About the Quill™ Self-Retaining System (SRS) The innovative Quill™ SRS represents the next generation of wound closure technology. A patented helical barbed design enables surgeons to suture without the use of knots. The absence of knots provides a wide range of clinical and economic benefits, including: Potential to improve patient outcomes: • Minimizes complications associated with knots • Potential to improve wound healing • May enhance cosmesis Potential to save time in the operating room: • Achieves potentially significant time savings, especially in suture intensive procedures Enhanced procedural techniques: • Allows closure of difficult wounds • Enables suturing in tight places • Allows the surgeon to control tension